Moderna-Merck AI-assisted cancer vaccine succeeds in Phase 3 trial

Moderna's stock surged over 110% after its AI-assisted personalized mRNA cancer vaccine cut melanoma recurrence in the first positive Phase 3 trial of its kind. Moderna and Merck sequence each patient's tumor against healthy DNA, and AI helps identify which mutations to target.